nach oben

Erschienen in:

03.10.2017 | Original Article

Clinicopathological features of primary splenic follicular lymphoma

verfasst von: Joji Shimono, Hiroaki Miyoshi, Tomohiko Kamimura, Tetsuya Eto, Takuto Miyagishima, Yuya Sasaki, Daisuke Kurita, Keisuke Kawamoto, Koji Nagafuji, Masao Seto, Takanori Teshima, Koichi Ohshima

Erschienen in: Annals of Hematology | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Follicular lymphoma (FL) is a low-grade lymphoma that is usually characterized by generalized lymphadenopathy. Extranodal invasion by FL generally involves the bone marrow, skin, and duodenum; splenic infiltration often occurs in the advanced stages. However, primary splenic FL is very rare. Hence, few studies have been performed on splenic FL, and its clinicopathological features have not been established. This study aimed to investigate the clinicopathological features of primary splenic FL, as compared to nodal FL. We analyzed 17 patients diagnosed with primary splenic FL and 153 control patients with systemic FL. Hepatitis C virus (HCV)-positive status was significantly more common in patients with splenic FL than in the control patients (p = 0.02). Ann Arbor stage III or IV (p = 0.0003) and high-risk FLIPI (Follicular Lymphoma International Prognostic Index) (p = 0.03) were significantly less common in patients with splenic FL than in the control patients; however, the overall and progression-free survival curves were not significantly different between the groups. Among the 17 patients with splenic FL, the progression-free survival was significantly worse in patients who underwent splenectomy without receiving postoperative chemotherapy than in those who did (p = 0.03). These results suggest that primary splenic FL should be considered different from systemic FL; accordingly, its management should also be conducted differently.

Nur mit Berechtigung zugänglich

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2009) World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon

Nakamura S, Ichimura K, Sato Y, Nakamura S, Nakamine H, Inagaki H, Sadahira Y, Ohshima K, Sakugawa S, Kondo E, Yanai H, Ohara N, Yoshino T (2006) Follicular lymphoma frequently originates in the salivary gland. Pathol Int 56:576–583CrossRefPubMed

Bacon CM, Ye H, Diss TC, McNamara C, Kueck B, Hasserjian RP, Rohatiner AZ, Ferry J, Du MQ, Dogan A (2007) Primary follicular lymphoma of testis and epididymis in adults. Am J Surg Pathol 31:1050–1058CrossRefPubMed

Grange F, Bekkenk MW, Wechsler J, Meijer CJ, Cerroni L, Bernengo M, Bosq J, Hedelin G, Fink Puches R, van Vloten WA, Joly P, Bagot M, Willemze R (2001) Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 19:3602–3610CrossRefPubMed

Yoshino T, Miyake K, Ichimura K, Mannami T, Ohara N, Hamazaki S, Akagi T (2000) Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol 24:688–693CrossRefPubMed

Bende RJ, Smit LA, van Noesel CJ (2007) Molecular pathways in follicular lymphoma. Leukemia 21:18–29CrossRefPubMed

Kimura Y, Sato K, Arakawa F, Karube K, Nomura Y, Shimizu K, Aoki R, Hashikawa K, Yoshida S, Kiyasu J, Takeuchi M, Nino D, Sugita Y, Morito T, Yoshino T, Nakamura S, Kikuchi M, Ohshima K (2010) Mantle cell lymphoma shows three morphological evolutions of classical, intermediate, and aggressive forms, which occur in parallel with increased labeling index of cyclin D1 and Ki-67. Cancer Sci 101:806–814CrossRefPubMed

Iannito E, Tripodo C (2011) How I diagnose and treat splenic lymphomas. Blood 117:2585–2595CrossRef

Shimizu-Kohno K, Kimura Y, Kiyasu J, Miyoshi H, Yoshida M, Ichikawa R, Niino D, Ohshima K (2012) Malignant lymphoma of the spleen in Japan: a clinicopathological analysis of 115 cases. Pathol Int 62:577–582CrossRefPubMed

10.

Howard MT, Dufresne S, Swerdlow SH, Cook JR (2009) Follicular lymphoma of the spleen: multiparameter analysis of 16 cases. Am J Clin Pathol 131:656–662CrossRefPubMed

11.

Mollejo M, Rodríguez-Pinilla MS, Montes-Moreno S, Algara P, Dogan A, Cigudosa JC, Juarez R, Flores T, Forteza J, Arribas A, Piris MA (2009) Splenic follicular lymphoma: clinicopathologic characteristics of a series of 32 cases. Am J Surg Pathol 33:730–738CrossRefPubMed

12.

Skarin AT, Davey FR, Moloney WC (1971) Lymphosarcoma of the spleen. Results of diagnostic splenectomy in 11 patients. Arch Intern Med 127:259–265CrossRefPubMed

13.

Kehoe J, Straus DJ (1988) Primary lymphoma of the spleen. Clinical features and outcome after splenectomy. Cancer 62:1433–1438CrossRefPubMed

14.

Miyoshi H, Sato K, Yoshida M, Kimura Y, Kiyasu J, Ichikawa A, Ishibashi Y, Arakawa F, Nakamura Y, Nakashima S, Niino D, Sugita Y, Ohshima K (2014) CD5-positive follicular lymphoma characterized by CD25, MUM1, low frequency of t(14;18) and poor prognosis. Pathol Int 64:95–103CrossRefPubMed

15.

Yoshida M, Ichikawa A, Miyoshi H, Takeuchi M, Kimura Y, Nino D, Ohshima K (2012) High frequency of t(14;18) in Hodgkin’s lymphoma associated with follicular lymphoma. Pathol Int 62:518–524CrossRefPubMed

16.

Karube K, Martínez D, Royo C, Navarro A, Pinyol M, Cazorla M, Castillo P, Valera A, Carrió A, Costa D, Colomer D, Rosenwald A, Ott G, Esteban D, Giné E, López-Guillermo A, Campo E (2014) Recurrent mutations of NOTCH genes in follicular lymphoma identify a distinctive subset of tumors. J Pathol 234:423–430CrossRefPubMed

17.

Yoshida N, Miyoshi H, Kato T, Sakata-Yanagimoto M, Niino D, Taniguchi H, Moriuchi Y, Miyahara M, Kurita D, Sasaki Y, Shimono J, Kawamoto K, Utsunomiya A, Imaizumi Y, Seto M, Ohshima K (2016) CCR4 frameshift mutation identifies a distinct group of adult T cell leukemia/lymphoma with poor prognosis. J Pathol 238:621–626CrossRefPubMed

18.

Kalpadakis C, Pangalis GA, Vassilakopoulous TP, Sachanas S, Angelopoulou MK (2014) Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned? Leuk Lymphoma 55:1463–1470CrossRefPubMed

19.

Xing KH, Kahlon A, Skinnider BF, Connors JM, Gascoyne RD, Sehn LH, Savage KJ, Slack GW, Shenkier TN, Klasa R, Gerrie AS, Villa D (2015) Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. Br J Haematol 169:520–527CrossRefPubMed

20.

Troussard X, Valensi F, Duchayne E, Garand R, Felman P, Tulliez M, Henry-Amar M, Bryon PA, Flandrin G (1996) Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groups Francais d’Hématologie Cellulaire (GFHC). Br J Haematol 93:731–736CrossRefPubMed

21.

Lenglet J, Traullé C, Mounier N, Benet C, Munoz-Bongrand N, Amorin S, Noguera ME, Traverse-Glehen A, Ffrench M, Baseggio L, Felman P, Callet-Bauchu E, Brice P, Berger F, Salles G, Brière J, Coiffier B, Thieblemont C (2014) Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma 55:1854–1860CrossRefPubMed

22.

Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R, Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G (2012) The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 209:1537–1551CrossRefPubMedPubMedCentral

23.

De Renzo A, Perna F, Persico M, Notaro R, Mainolfi C, de Sio I, Ciancia G, Picardi M, Del Vecchio L, Pane F, Rotoli B (2008) Excellent prognosis and prevalence of HCV infection of primary hepatic and splenic non-Hodgkin’s lymphoma. Eur J Haematol 81:51–57CrossRefPubMed

24.

Takeshita M, Sakai H, Okamura S, Oshiro Y, Higaki K, Nakashima O, Uike N, Yamamoto I, Kinjo M, Matsubara F (2005) Splenic large B-cell lymphoma in patients with hepatitis C virus infection. Hum Pathol 36:878–885CrossRefPubMed

25.

Michot JM, Canioni D, Driss H, Alric L, Cacoub P, Suarez F, Sibon D, Thieblemont C, Dupuis J, Terrier B, Feray C, Tilly H, Pol S, Leblond V, Settegrana C, Rabiega P, Barthe Y, Hendel-Chavez H, Nguyen-Khac F, Merle-Béral H, Berger F, Molina T, Charlotte F, Carrat F, Davi F, Hermine O, Besson C, ANRS HC-13Lympho-C Study Group (2015) Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol 90:197–203CrossRefPubMed

26.

Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, Visentini M, Torres HA, Loustaud-Ratti V, Peveling-Oberhag J, Fabris P, Rossotti R, Zaja F, Rigacci L, Rattotti S, Bruno R, Merli M, Dorival C, Alric L, Jaccard A, Pol S, Carrat F, Ferretti VV, Visco C, Hermine O (2016) Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood 128:2527–2532CrossRefPubMed

27.

Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D, Rowe JM (2001) The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 97:1555–1559CrossRefPubMed

28.

Chan CH, Hadlock KG, Foung SK, Levy S (2001) V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 97:1023–1026CrossRefPubMed

29.

Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D, Rowe J (2001) bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection. Br J Haematol 112:364–369CrossRefPubMed

30.

Giannelli F, Moscarella S, Giannini C, Caini P, Monti M, Gragnani L, Romanelli RG, Solazzo V, Laffi G, La Villa G, Gentilini P, Zignego AL (2003) Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood 102:1196–1201CrossRefPubMed

31.

Poetsch M, Weber-Matthiesen K, Plendl HJ, Grote W, Schlegelberger B (1996) Detection of the t(14;18) chromosomal translocation by interphase cytogenetics with yeast-artificial-chromosome probes in follicular lymphoma and nonneoplastic lymphoproliferation. J Clin Oncol 14:963–969CrossRefPubMed

Titel: Clinicopathological features of primary splenic follicular lymphoma
verfasst von: Joji Shimono
Hiroaki Miyoshi
Tomohiko Kamimura
Tetsuya Eto
Takuto Miyagishima
Yuya Sasaki
Daisuke Kurita
Keisuke Kawamoto
Koji Nagafuji
Masao Seto
Takanori Teshima
Koichi Ohshima
Publikationsdatum: 03.10.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 12/2017
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-017-3139-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2017

High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma

Relapsed subcutaneous panniculitis-like T cell lymphoma: role of haploidentical hematopoietic stem cell transplant

Horse versus rabbit antithymocyte globulin in immunosuppressive therapy of treatment-naïve aplastic anemia: a systematic review and meta-analysis

The prognostic significance of serum XCL1 concentration in patients with acute lymphoblastic leukemia: a pilot study

Leonine facies due to Sezary syndrome: complete clinical, radiologic, and molecular remission with alemtuzumab